The Over/Under On Cannabis MSOs
Marijuana growers in the U.S. have it harder than their Canadian counterparts, but a team of analysts at one firm are bullish on a select… Read More »The Over/Under On Cannabis MSOs
Marijuana growers in the U.S. have it harder than their Canadian counterparts, but a team of analysts at one firm are bullish on a select… Read More »The Over/Under On Cannabis MSOs
They may be dinged, scratched or dented, but these companies are far from junk. Rather, says one outperforming fund manager, they are high-quality companies that… Read More »These Stocks Are Dented, But Far From Dead
Amid an escalating trade war and increasing market volatility, one of the very few ‘bright spots’ in the markets – outside of precious metals –… Read More »Charting Solar’s Path
Two small biotech companies focused on underserved medical needs and patient populations – including neuropsychiatric/neurological disorders and women’s health issues – are among five Buy-rated… Read More »Big Upside Potential At Low Prices For Aggressive Traders
What has happened to some of the most promising (and popular) marijuana stocks? Here’s a look at three beaten-down pot stocks – and whether they… Read More »Beaten Down In A Budding Space
If you’re still getting your feet wet in the pot stock pool, the best stocks to consider may be the biggest players in the market.… Read More »The Biggest Players In Pot
They helped create – and sustain – the longest bull market in history by driving tech stocks and pot stocks higher. But now, as Millennials… Read More »“Peak FANG, Peak Pot, Peak Millennials” – And The End Of The Bull Market?
Ranging from ~4.5% to 5.9%, these three Dogs of the Dow have the highest dividend yields in the Dow – and their already generous yields… Read More »Get More Bite From The Highest-Yielding Dogs
If you had followed Jay Soloff’s 2018 trades, with a little luck, you could’ve turned $500 into as much as $678,906. That sounds unbelievable. But… Read More »$500 into $678,906?
Healthcare stocks have lagged overall this year, in large part due to political and regulatory risks. Some healthcare stocks, however, appear to be shielded from… Read More »Healthcare Stocks With Political Immunity